Evotec Subsidiary Just Evotec Biologics Advances U.S. Preparedness Efforts with New Antibody Manufacturing Initiative for Filovirus Threats

Evotec Subsidiary Just Evotec Biologics Advances U.S. Preparedness Efforts with New Antibody Manufacturing Initiative for Filovirus Threats

(IN BRIEF) Evotec SE’s subsidiary Just – Evotec Biologics has been selected by the Biomedical Advanced Research and Development Authority BioMaP Consortium to support a multi-year initiative aimed at improving manufacturing processes for antibody-based treatments targeting Ebola and Sudan virus. The program, which could reach up to $10 million in value, focuses on enhancing scalability, efficiency, and affordability in biologics production. By leveraging antibodies identified in Ebola survivors and applying advanced manufacturing technologies, the project aims to address the lack of approved treatments for Sudan virus while strengthening the U.S. response to future outbreak scenarios.

(PRESS RELEASE) HAMBURG, 24-Mar-2026 — /EuropaWire/ — Evotec SE has announced that its U.S.-based biologics arm, Just – Evotec Biologics, has been chosen to contribute to a U.S. government-supported effort focused on strengthening readiness against severe viral outbreaks. The selection comes through the Biomedical Advanced Research and Development Authority BioMaP Consortium, which is working to advance production strategies for a monoclonal antibody combination aimed at filovirus infections such as Ebola and Sudan virus.

The collaboration spans multiple years and carries a potential value of up to $10 million, depending on the activation of additional program phases. It is designed to improve national preparedness by enabling the development of more affordable and scalable therapeutic solutions. Although treatments are available for Ebola virus disease, there remains a significant unmet need for effective options targeting Sudan virus, underscoring the importance of this initiative.

As part of the agreement, Just – Evotec Biologics will apply its integrated technology platform to enhance several key stages of biologics manufacturing. This includes refining antibody structures, establishing optimized cell lines, and building efficient, large-scale production workflows. The antibodies at the center of the project were originally discovered in individuals who survived the 2014 Ebola outbreak, offering valuable insight into naturally occurring protective immune responses. The company’s role is to transform these findings into manufacturable therapies that can be produced rapidly and at scale during emergency situations.

Linda Zuckerman, Executive Vice President and Global Head of Biotherapeutics at Just – Evotec Biologics, highlighted that rapid and dependable production capabilities are essential when responding to infectious disease crises. She noted that the company’s platform is engineered to deliver high-yield outputs and consistent quality, helping ensure timely availability of treatments when outbreaks occur.

Funding for the program is being provided by the U.S. Department of Health and Human Services through its Administration for Strategic Preparedness and Response, reinforcing ongoing efforts to expand the country’s capacity to respond to emerging health threats.

About BARDA

The Biomedical Advanced Research and Development Authority (BARDA) within the U.S Department of Health and Human Services’ (HHS) Administration for Strategic Preparedness and Response (ASPR) is responsible for the advanced research, development, and procurement of medical countermeasures, for chemical, biological, radiological and nuclear (CBRN) threats, as well as pandemic influenza and emerging infectious diseases.

About the Biopharmaceutical Manufacturing Preparedness Consortium

The Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium) supports BARDA and is comprised of industry partners across the drug and vaccine manufacturing supply chain, including manufacturers of required raw materials and consumables, developers of innovative manufacturing technologies, and suppliers of fill finish services. The consortium seeks to expand the industrial and manufacturing base for medical countermeasures to include the requisite capabilities, flexibilities, and strategies to secure needed medical supplies to prepare the United States for future health security threats. Visit biomap-consortium.org to learn more and follow @BioMaP-Consortium on LinkedIn.

About Just – Evotec Biologics

Just – Evotec Biologics, wholly owned by Evotec SE, is a first-to-industry biologics platform company that leverages AI/ML technologies and world-leading molecular design, cell line development, process intensification and continuous manufacturing strategies to advance biotherapeutics from discovery through clinical stages to commercial launch. The Just – Evotec Biologics team combines deep industry experience in the fields of data, protein, process, and manufacturing sciences including automation with highly integrated and flexible capabilities to break through the scientific and economic barriers associated with the development of protein therapeutics. Our focus is to accelerate and expand access to biotherapeutics through scientific and technological innovation for our proprietary projects and on behalf of our partners. Learn more at www.just-evotecbiologics.com.

About Evotec SE

Evotec is a life science company that is pioneering the future of drug discovery and development. By integrating breakthrough science with AI-driven innovation and advanced technologies, we accelerate the journey from concept to cure — faster, smarter, and with greater precision. Our expertise spans small molecules, biologics, cell therapies and associated modalities, supported by proprietary platforms such as Molecular Patient Databases, PanOmics and iPSC-based disease modeling. With flexible partnering models tailored to our customers’ needs, we work with all Top 20 Pharma companies, over 800 biotechs, academic institutions, and healthcare stakeholders. Our offerings range from standalone services to fully integrated R&D programs and long-term strategic partnerships, combining scientific excellence with operational agility. Through Just – Evotec Biologics, we redefine biologics development and manufacturing to improve accessibility and affordability. With a strong portfolio of over 100 proprietary R&D assets, most of them being co-owned, we focus on key therapeutic areas including oncology, cardiovascular and metabolic diseases, neurology, and immunology. Evotec’s global team of more than 4,800 experts operates from sites in Europe and the U.S., offering complementary technologies and services as synergistic centers of excellence. Learn more at www.evotec.com and follow us on LinkedIn and X/Twitter @Evotec.

Forward-looking statements

This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec’s securities. Words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “should,” “target,” “would” and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding Evotec’s expectations for revenues, Group EBITDA and unpartnered R&D expenses. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

Media Contact:

Investor Relations
Dr. Sarah Fakih
EVP Head of Global Communications & Investor Relations Sarah.Fakih@evotec.com

SOURCE: Evotec